Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Micromedic Technologies

MicroRNAs Are Regulators and Biomarkers of Bone Cancer Metastasis

By BiotechDaily International staff writers
Posted on 30 Oct 2013
Print article
Image: Researchers at Princeton University have found that microRNAs may serve as both therapeutic targets and predictors of metastasis. In this image, breast cancer cells (right) spread toward the hindlimb bone (left), using the host's own osteoclasts to continue their advance (Photo courtesy of Dr. Yibin Kang, Princeton University).
Image: Researchers at Princeton University have found that microRNAs may serve as both therapeutic targets and predictors of metastasis. In this image, breast cancer cells (right) spread toward the hindlimb bone (left), using the host's own osteoclasts to continue their advance (Photo courtesy of Dr. Yibin Kang, Princeton University).
Different groups of microRNAs (miRNAs) have been found to either inhibit or promote metastasis of cancer in the bone, which occurs in about 70% of patients with late-stage cancer.

Investigators at Princeton University (Princeton, NJ, USA) reported in the October 14, 2013, edition of the journal Cancer Cell that miR-141 and miR-219 inhibited metastasis by targeting osteoclast genes. Intravenous delivery of these miRNAs in vivo inhibited osteoclast activity and reduced osteolytic bone metastasis.

In contrast, serum levels of sICAM1 (soluble intracellular adhesion molecule) and two osteoclast miRNAs, miR-16 and miR-378, which were elevated in osteoclast differentiation, correlated with increased bone metastasis in mouse models.

"The tumor uses the osteoclasts as forced labor," said senior author Dr. Yibin Kang, professor of molecular biology at Princeton University. "We ultimately hope to extend mice experimentation to clinical trials. In the end, we want to help the patients."

The authors suggested that the findings published in the Cancer Cell paper establish miRNAs as potential therapeutic targets and clinical biomarkers of bone metastasis.

Related Links:

Princeton University



Print article

Channels

Drug Discovery

view channel
Image: The “cellXpress” automated imaging analysis software enables to efficiently and accurately detect cellular responses (reflected in green) to nephrotoxic compounds (Photo courtesy of Agency for Science, Technology and Research (Singapore)).

First High-Throughput Imaging Platform for Predicting Kidney Toxicity of Chemicals

Researchers have developed a high-throughput platform of automated cellular imaging that efficiently and accurately predicts renal toxicity of chemical compounds without animal testing, providing an improved... Read more

Business

view channel

Purchase Agreement to Boost Ebola Vaccine Development

A deal to help boost development of a vaccine to protect against Ebolavirus infection was finalized at the recent Davos Conference in Switzerland. Gavi (Geneva, Switzerland), the global alliance for vaccines and immunizations, announced that it would spend five million USD to purchase the Ebola vaccine under development... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.